Tag: TROP-2

Triple-negative breast cancer (TNBC) remains one of the most challenging and most malignant subtypes of breast cancer to treat. TNBC represents a heterogeneous group...

Antibody-drug conjugates (ADCs) have become a mainstay in targeted cancer therapies, but their effectiveness can be limited by tumor antigen heterogeneity and acquired resistance.

Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan Accepted by China's Center for Drug Evaluation

Datopotamab deruxtecan (Datroway®; Daiichi Sankyo, previously known as DS-1062 and TROP2 ADC, see ADC Drug Map) an antibody-drug conjugate or ADC, being jointly developed and commercialized globally by Daiichi Sankyo and AstraZeneca, has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy.

VBC103 (VelaVigo Cayman) is a bispecific ADC that selectively targets both TROP-2 and Nectin4, which are highly co-expressed in urothelial carcinoma, TNBC, and other tumors.

Gilead Sciences and Strata Oncology have signed an agreement in which Gilead has agreed to collaborate on the Strata Precision Indications for Approved THerapies (Strata PATH™; NCT05097599) study by providing sacituzumab govitecan-hziy (Trodelvy®) for eligible patients with cancer.

Results from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating sacituzumab govitecan-hziy (Trodelvy®; Gilead Sciences) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients...

Earlier today the U.S. Food and Drug Administration (FDA) confirmed that it has accepted Immunomedics' Resubmission of the Biologics License Application (BLA) for sacituzumab...

With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...